Financial News with AI Impact Scores

Solar Stocks Rally: First Solar, ETFs Bask In Treasury Tax Boost

Solar stocks experienced a rebound following new tax credit guidance from the U.S. Treasury and IRS, with First Solar (NASDAQ: FSLR) leading the rally, gaining over 10% after the elimination of the '5% safe harbor' rule for large-scale projects. The Invesco Solar ETF (NYSE: TAN) also saw a nearly 5% increase, benefiting from First Solar's policy clarity. Other ETFs like the iShares Global Clean Energy ETF (NASDAQ: ICLN) and First Trust NASDAQ Clean Edge Green Energy Index Fund (NASDAQ: QCLN) rose over 2%, indicating a broader positive impact on the clean energy sector.

Shares of aluminum stocks are trading lower after the US expanded products subject to aluminum tariffs.

Shares of aluminum stocks are trading higher after the US expanded products subject to aluminum tariffs.

As Meta Faces AI Scrutiny, Mounting Regulatory Risk Overshadows Strong Earnings And Pushes Stock Lower

Meta Platforms Inc (NASDAQ: META) is facing regulatory scrutiny following reports of a leaked internal AI rulebook that allowed chatbots to engage in inappropriate conversations with children, prompting calls for investigation from U.S. Senators. Despite strong earnings growth, with performance three times faster than the S&P 500, the company's stock has dropped 2.50% to $765.60 amid concerns over internal instability and competition in its AI division. Meta is undergoing its fourth major AI restructuring in six months and has recently settled a lawsuit regarding AI bias, further complicating its operational landscape.

BridgeBio Oncology Therapeutics shares are trading higher after Wedbush initiated coverage on the stock with an Outperform rating and announced a price target of $25.

Michael Burry's Beauty Bet: $40 Million In Estée Lauder Options

Michael Burry's Scion Asset Management has made significant moves in Estée Lauder Companies, Inc. (NYSE: EL), selling 50,000 shares, reducing his stake by 25%, while acquiring 500,000 call option contracts valued at approximately $40.4 million. Despite the sale, Estée Lauder remains Burry's largest holding with 150,000 shares worth $12.12 million. The company is expected to report fourth-quarter earnings of nine cents per share on revenue of $3.4 billion, which could enhance Burry's position if results exceed expectations.

Bitcoin, Ethereum, XRP Headed For September Crash? Watch Out, Analyst Warns

Analyst Benjamin Cowen predicts a significant correction for Bitcoin, Ethereum, and altcoins in September, drawing on historical trends from 2013, 2017, and 2021. He anticipates Bitcoin could drop approximately 6% to its support levels around $110,000–$115,000, while Ethereum may see a decline of 20–30% after a brief peak. Altcoins are expected to experience even deeper losses of 30–50%. Cowen also highlighted macroeconomic risks, noting that a potential Federal Reserve rate cut could lead to increased bond yields, further impacting market stability.

Meta shares are trading lower amid reports of the company faces congressional scrutiny, with some US senators calling for an investigation.

This Rare Signal Last Flashed In 1998—Then Stocks Took Off

In mid-August 2025, the spread between U.S. investment-grade corporate bonds and Treasury yields fell to 75 basis points, the lowest since June 2008, indicating strong investor confidence in corporate debt. This narrowing spread allows companies to borrow at rates nearly equivalent to U.S. Treasuries, boosting corporate investment and potential shareholder returns. The investment-grade credit market has seen a broad rally, contrasting with the narrow equity rally dominated by a few tech giants, suggesting a bullish signal reminiscent of the 1998 market conditions.

Aspire Shares Are Trading Higher Monday: What's Going On?

Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) shares rose 80.67% to 65 cents following the announcement of positive top-line data from a bioavailability trial of its new sublingual aspirin product, which demonstrated faster and more effective results compared to standard chewed aspirin. The treatment was reported to be safe and well-tolerated, with no side effects. The company plans to discuss the results with the FDA to support a potential application for accelerated approval.